Incidence and Progression of Chronic Kidney Disease After Hepatitis C Seroconversion: Results from ERCHIVES

Digestive Diseases and Sciences

Volumn 61, Issue 3, 2016, Pages 930-936

  Rogal, Shari S ^a,b   Yan, Peng ^a   Rimland, David ^c,d   Re, Vincent Lo ^e   Al Rowais, Hind ^f   Fried, Linda ^a,f   Butt, Adeel A ^a,f,g,h  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g HAMAD MEDICAL CORPORATION   (Qatar)

^h Hamad Healthcare Quality Institute   (Qatar)

Author keywords

CKD; HCV; Progressive CKD

Indexed keywords

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEROCONVERSION; VETERAN; AGE; BLOOD; COMORBIDITY; DIABETES MELLITUS; HYPERTENSION; INCIDENCE; LIVER CIRRHOSIS; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS; UNITED STATES; VIRUS LOAD;

VIRUS RNA;

ADULT; AGE FACTORS; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HUMANS; HYPERTENSION; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; SEROCONVERSION; SEX FACTORS; SUBSTANCE-RELATED DISORDERS; UNITED STATES; VETERANS; VIRAL LOAD;

EID: 84958878333     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3918-z     Document Type: Article

References (32)

1. Global Burden of Disease Study C. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800.
2. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002;36:1439–1445.
3. Molnar MZ, Alhourani HM, Wall BM, et al. Association of hepatitis C virus infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology. 2014;61:1495–1502.
4. Fabrizi F, Martin P, Dixit V, Messa P. Hepatitis C virus infection and kidney disease: A meta-analysis. Clin J Am Soc Nephrol. 2012;7:549–557.
5. Butt AA, Wang X, Fried LF. HCV infection and the incidence of CKD. Am J Kidney Dis. 2011;57:396–402.
6. Park H, Adeyemi A, Henry L, et al. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat. 2015;22:897–905.
7. Butt AA, Yan P, Lo Re V III, et al. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med. 2014;175:178–185.
8. Butt AA, Yan P, Shaikh OS, et al. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings. J Viral Hepat. 2014;22:691–700.
9. Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology. 2009;50:387–392.
10. Mohanty A, Erqou S, McGinnis KA, et al. Therapy for hepatitis C virus infection increases survival of patients with pretreatment anemia. Clin Gastroenterol Hepatol. 2013;11:741–747, e3.
11. Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2010;55:648–659.
12. Bash LD, Coresh J, Kottgen A, et al. Defining incident chronic kidney disease in the research setting: The ARIC study. Am J Epidemiol. 2009;170:414–424.
13. Elsayed EF, Sarnak MJ, Tighiouart H, et al. Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. Am J Kidney Dis. 2008;52:29–38.
14. Yu B, Zheng Y, Nettleton JA, Alexander D, Coresh J, Boerwinkle E. Serum metabolomic profiling and incident CKD among African Americans. Clin J Am Soc Nephrol. 2014;9:1410–1417.
15. Driver TH, Shlipak MG, Katz R, et al. Low serum bicarbonate and kidney function decline: The Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis. 2014;64:534–541.
16. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32–36.
17. Lo Re V III, Lim JK, Goetz MB, et al. Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf. 2011;20:689–699.
18. Tsui JI, Vittinghoff E, Shlipak MG, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med. 2007;167:1271–1276.
19. Su FH, Su CT, Chang SN, et al. Association of hepatitis C virus infection with risk of ESRD: A population-based study. Am J Kidney Dis. 2012;60:553–560.
20. Visentin M, Zhao R, Goldman ID. Augmentation of reduced folate carrier-mediated folate/antifolate transport through an antiport mechanism with 5-aminoimidazole-4-carboxamide riboside monophosphate. Mol Pharmacol. 2012;82:209–216.
21. Molnar MZ, Alhourani HM, Wall BM, et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology. 2015;61:1495–1502.
22. Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol. 2009;4:207–220.
23. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: An update. Am J Kidney Dis. 2003;42:631–657.
24. Morales JM, Kamar N, Rostaing L. Hepatitis C and renal disease: Epidemiology, diagnosis, pathogenesis and therapy. Contrib Nephrol. 2012;176:10–23.
25. Cediel E, Vazquez-Cruz B, Navarro-Cid J, et al. Role of endothelin-1 and thromboxane A2 in renal vasoconstriction induced by angiotensin II in diabetes and hypertension. Kidney Int Suppl. 2002. doi:10.1046/j.1523-1755.62.s82.2.x.
26. Lonardo A, Loria P, Carulli N. Dysmetabolic changes associated with HCV: A distinct syndrome? Intern Emerg Med. 2008;3:99–108.
27. Vart P, Gansevoort RT, Crews DC, Reijneveld SA, Bultmann U. Mediators of the association between low socioeconomic status and chronic kidney disease in the United States. Am J Epidemiol. 2015;181:385–396.
28. Buettner M, Toennes SW, Buettner S, et al. Nephropathy in illicit drug abusers: A postmortem analysis. Am J Kidney Dis. 2014;63:945–953.
29. Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2014;64:495–503.
30. Hsu YC, Lin JT, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59:1293–1302.
31. Shire NJ, Rao MB, Succop P, et al. Improving noninvasive methods of assessing liver fibrosis in patients with hepatitis C virus/human immunodeficiency virus co-infection. Clin Gastroenterol Hepatol. 2009; 7:471–480, e471–472.
32. Caregaro L, Menon F, Angeli P, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med. 1994;154:201–205.